CHEMOTHERAPY COMMITTEE: CANCER AND LEUKEMIA GROUP B

尽管已经对大多数主要药物进行了详细的药代动力学研究， 目前使用的抗癌药物，血浆中药物浓度的测定， 脑脊液和尿还没有被常规地用来确定 生物利用度的变化，并相应地调整剂量。 我们希望 通过这笔赠款提供这些数据，以补充方案药物试验 由CALGB执行。 通过几个剂量达到的阿糖胞苷水平， 目前正在分析给药时间表。 计划在 随后进行铂类似物，甲氨蝶呤， 阿霉素和长春花生物碱，以确定间和 患者内变异性，由于路线或时间表的变化，及其 生物利用度与毒性和治疗益处的关系。 这些研究将利用CALGB内现有的专门知识和设施 按照化疗方案确定的优先顺序提供支持 CALGB委员会。

Although detailed pharmacokinetic studies have been performed on most major anticancer drugs currently in use, assays of drug concentration in plasma, cerebrospinal fluid and uring have not been routinely employed to determine variations in bioavailability and to adjust dosing accordingly. We wish through this grant to supply such data to supplement protocol drug trials conducted by the CALGB. Cytarabine levels achieved by several dosages and schedules of administration are currently being assayed. It is planned to follow this with drug level studies of platinum analogs, methotexate, adriamycin and vinca (Catharanthus) alkaloids to determine inter- and intrapatient variability, variations due to route or schedule, and their relationship of bioavailability to toxicity and to therapeutic benefit. These studies will use existing expertise and facilities within CALGB supported in sequence on priorities determined by the Chemotherapy Committee of CALGB.